ライフサイエンスコーパス: unfit

1 ning unfitness for intensive chemotherapy (F-unfit).

2 46 to 0.93) compared with those who remained unfit.

3 lvement, liver failure, and being surgically unfit.

4 (median age, 81 years), and 1,428 (87%) were unfit.

5 ometer and used to classify adults as fit or unfit.

6 may be destroyed if they are architecturally unfit.

7 m to eliminate Drosophila cells perceived as unfit.

8 n recommended, whilst 37% were classified as unfit.

9 ed, and African Americans as psychologically unfit.

10 s follows: 42.1% unassessed, 30.4% medically unfit, 16.9% unsuitable due to age, 3.1% psychologically

11 as 61% had significant comorbidity, 26% were unfit, 17% had a geriatric syndrome, and 13% had loss of

12 (sGA) that classifies patients as fit (55%), unfit (28%), and frail (18%) with significantly differen

13 ons (44.3% unfit, 56.9% fit), fatigue (15.8% unfit, 35.9% fit), and infections (57.5% unfit, 69.6% fi

14 6.9% fit), infusion-related-reactions (44.3% unfit, 56.9% fit), fatigue (15.8% unfit, 35.9% fit), and

15 Adverse events included neutropenia (62.7% unfit, 56.9% fit), infusion-related-reactions (44.3% unf

16 .8% unfit, 35.9% fit), and infections (57.5% unfit, 69.6% fit).

17 egimen, an FDA-approved therapy for older or unfit AML patients, significantly prolonging survival in

18 including those with expanded N termini and unfitting anchor residues.

19 unsuitable due to age, 3.1% psychologically unfit and 1.5% declined counsel.

20 dose reductions of <80% occurred in 39.6% of unfit and 17.6% of fit patients, with lower ORR (83.3% v

21 sidual disease (uMRD) at <10-4 were 80.3% in unfit and 85.1% in fit patients.

22 Overall response rate (ORR) was 89.5% in unfit and 96.1% in fit patients.

23 reported as unsuitable due to age, medically unfit and declined, and African Americans as psychologic

24 behavioural feasibility studies in extremely unfit and sedentary people.

25 rid offspring of different species are often unfit, and yet it has long been argued that introgressio

26 We conclude that the mouse is an unfit animal for exploring CRP-mediated activation of th

27 Compared with being unfit, being moderately or highly fit was associated wit

28 ts dying while waiting or becoming medically unfit by the time an organ is offered.

29 Being unfit carried a greater risk than any of the cardiac ris

30 We propose that removal of unfit cells from a population of terminally differentiat

31 xplained by the selection and elimination of unfit cells from the whole BMSC population.

32 as a quality control mechanism to eliminate unfit cells in favour of their more robust neighbours(1,

33 or clpP resulted in the extended survival of unfit cells in stationary phase, but at the cost of main

34 uld benefit from the capability to recognize unfit cells, because accumulation of damaged but viable

35 and offers an additional route to eliminate unfit cells.

36 a quality control mechanism that eliminates unfit cells.

37 xchange between cells signals elimination of unfit cells.

38 For 'unfit' cells to be detected, their competitive status ne

39 its components, preventing the production of unfit character combinations.

40 instead favoring the expansion of rarer and unfit chemosensitive clones.

41 enated and nutrient-replete tissues, but the unfit, damaged, and dysfunctional organelles generated b

42 g from centrosome loss prevent the growth of unfit daughter cells by activating a pathway involving 5

43 Extrusion is a mechanism used to eliminate unfit, excess, or dying cells from epithelial tissues.

44 among the unfit-not fat, and 1.57 among the unfit-fat women compared with fit-not fat women.

45 hen CRF was considered as a binary variable (unfit/fit), low fitness was the strongest predictor of r

46 ars and 13 younger than 41 years) considered unfit for a myeloablative allograft received an FMA redu

47 patients either exhausted or were considered unfit for all approved conventional treatments.

48 prednisolone (R-GCVP) in patients considered unfit for anthracycline-containing chemoimmunotherapy be

49 s in our study, rather than those failing or unfit for chemoradiotherapy.

50 ) is generally used palliatively in patients unfit for chemotherapy.

51 y enrolled patients aged >=60 years with cHL unfit for conventional chemotherapy to receive frontline

52 in ~70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy.

53 rrently, over 40% of patients are considered unfit for conventional open surgery, requiring a cardiop

54 All patients were considered unfit for conventional surgery.

55 e with less than a T0 response but medically unfit for cystectomy (six patients), received consolidat

56 large amounts of crop-based biomass that are unfit for direct human consumption but potentially suita

57 ring World War 1, with each affected soldier unfit for duty for more than 60 days.

58 ith alkylating agents in patients considered unfit for fludarabine, cyclophosphamide, and rituximab,

59 with chronic lymphocytic leukaemia who were unfit for fludarabine-based treatment, and whether this

60 an ECOG performance status of 0-2, and were unfit for fludarabine-based treatment.

61 vanced colorectal cancer who were considered unfit for full-dose chemotherapy.

62 s were judged, beyond this period, fish were unfit for human consumption as revealed by complementary

63 m residue level by 1-12 folds, and thus were unfit for human consumption.

64 mycotoxin contamination of grain, making it unfit for human consumption.

65 However, common photonic crystals are unfit for in-operando on/off controls.

66 ial alternatives for older patients with cHL unfit for initial conventional chemotherapy.

67 ine-containing backbone in younger patients, unfit for intensive chemotherapy, as well as comparisons

68 or patients with newly diagnosed AML who are unfit for intensive chemotherapy.

69 eukaemia (AML) who are 75 years or older, or unfit for intensive chemotherapy.

70 with low-intensity therapy in older patients unfit for intensive chemotherapy.

71 can generates false information, making them unfit for many research problems.

72 in-1 (NPM1) mutation generated myeloid cells unfit for normal hematopoiesis but prone to immunogenic

73 Patients were designated as fit or unfit for oAAA by the treating surgeon.

74 Patients unfit for oAAA had higher rates of cardiac (7.8% versus

75 Finally, patients designated as unfit for oAAA had worse survival, even adjusting for pa

76 cm, designation by the operating surgeon as unfit for oAAA provides insight into both short- and lon

77 ng EVAR with AAAs <6.5 cm who are considered unfit for oAAA.

78 1653 EVARs, 309 (18.7%) patients were deemed unfit for oAAA.

79 rysms (AAAs) considered preoperatively to be unfit for open AAA repair (oAAA).

80 atient characteristics associated with being unfit for open repair and predictors of survival using m

81 t been shown to improve survival in patients unfit for open repair.

82 ir with observation in 338 patients who were unfit for open repair.

83 rbidities, and 19.5% would be categorized as unfit for open repair.

84 VER trial excluded high-risk patients deemed unfit for open repair.

85 nts with other ocular and systemic diseases, unfit for optical biometry measurements due to dense cat

86 s to treat VL, because current therapies are unfit for purpose in a resource-poor setting.

87 conclude the current rbcL + matK barcode is unfit for purpose.

88 For those with stage IV disease or unfit for radical treatment, a variety of palliative mod

89 Patients unfit for RC, radiation, or cisplatin-based chemotherapy

90 adates, showing conventional treatment to be unfit for reducing overall toxicity.

91 In patients unfit for resection, newer endoscopic ablative technique

92 awbacks as they can be time consuming, hence unfit for scale, and often lack standardization and a fi

93 illing to undergo surgery, or were medically unfit for surgery were randomly assigned to receive eith

94 nder either had unresectable disease or were unfit for surgery.

95 l high-resolution CT characteristics but are unfit for surgical lung biopsy, therefore preventing a c

96 aling inhibition and taxane chemotherapy (or unfit for taxane), who were treated with (177)Lu-PSMA-61

97 poor functional group tolerance renders them unfit for the synthesis of naturally occurring polypheno

98 ease, particularly among patients considered unfit for traditional open resection.

99 f patients were delisted because they became unfit for transplantation.

100 surgery the first intended recipient became unfit for transplantation.

101 41%), retired (31%), or permanently declared unfit for work (26%).

102 t depression status, we identified medically unfit for work, proteinuria, lower physical activity lev

103 es associated with depression were medically unfit for work, proteinuria, lower physical activity lev

104 isease who have not already received, or are unfit for, chemoradiotherapy.

105 astatic urothelial carcinoma are considered "unfit" for cisplatin.

106 with urothelial cancer who are ineligible ("unfit") for cisplatin chemotherapy.

107 only supportive care should be considered in unfit, frail patients.

108 Furthermore, this organization eliminates unfit genotypes, providing a fitness advantage to the po

109 GS-CA1 selects in vitro for unfit GS-CA1-resistant capsid variants that remain fully

110 risk factors for childhood obesity are being unfit, having an obese father, and being large at birth.

111 disadvantage associated with the presence of unfit homozygotes.

112 ng person may become even more metabolically unfit in the coming years if they sit too much, thereby

113 syndrome components, and lower fatness than unfit individuals across BMI categories.

114 Survival improved significantly when unfit individuals became fit.

115 Unfit individuals who improved their fitness status with

116 cal activity, particularly when performed by unfit individuals, can acutely increase the risk of sudd

117 A uniform definition of unfit is proposed on the basis of the results of a surve

118 Unfit, lean men also had a higher risk of all-cause and

119 In contrast, the fit-overweight and unfit-lean participants did not differ significantly fro

120 of a tightly binding host at the expense of unfit library members.

121 parental history of ischemic heart disease, unfit (low cardiorespiratory fitness as determined by ma

122 ization by traditional methods renders males unfit, making the creation of precise genetic sterilizat

123 in the murine heart that enables transfer of unfit material to preserve metabolic stability and organ

124 patients (median age, 67 years), 55.7% were unfit (median age, 72 years) and 44.3% were fit (median

125 en had significantly lower HF mortality than unfit men (P</=0.02).

126 Unfit men had a higher risk of all-cause and CVD mortali

127 ere significantly lower in fit compared with unfit men in normal and overweight body mass index strat

128 Similarly, unfit men with low waist girths (<87 cm) had greater ris

129 r risk factors on HF mortality in fit versus unfit men.

130 retical alternative to the technology-in-use unfit method detection limit (USEPA MDL); it is an essen

131 fitness landscape in which the most fit has unfit near-mutational neighbours, and a lower fitness pe

132 Inclusion of only relapsed-refractory, or unfit newly diagnosed, patients risks falsely negative r

133 were 1.32 among the fit-fat, 1.30 among the unfit-not fat, and 1.57 among the unfit-fat women compar

134 significantly lower visceral fat levels than unfit obese peers (-3.0; P = 0.03).

135 ysicians is to differentiate between fit and unfit older patients in order to offer both groups optim

136 In unfit older patients, a dynamic dosing strategy is often

137 Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, we

138 ostatic process that eliminates by apoptosis unfit or undesirable cells from animal tissues, includin

139 host fitness for standard therapy (ie, fit, unfit, or frail); (2) leukemia resistance (high vs low p

140 Unfit organisms were replaced, and the model self-organi

141 Compared with fit-lean participants, the unfit-overweight participants had significantly higher c

142 e benefit of frailty screening for detecting unfit patients and avoiding unnecessary GA in fit patien

143 ter-tolerated and investigational agents for unfit patients and those with adverse leukemia biology.

144 The purpose of this review is to define unfit patients and to identify treatment options for thi

145 Older and unfit patients can receive suitable multiagent chemother

146 standard Gem/CDDP regimen, in particular in unfit patients for CDDP.At second-line, selective patien

147 ligibility criteria have been used to define unfit patients in these studies.

148 therapeutic benefit of these drugs in older/unfit patients is limited to only a few months, highligh

149 al value of frailty screening is to identify unfit patients needing geriatric assessment (GA) and to

150 (G8) and modified G8 scores for identifying unfit patients was determined on the basis of GA results

151 th F-fit patients, the overall survival of F-unfit patients was significantly shorter (median, 4.8 mo

152 alysis, the net benefit (NB) for identifying unfit patients were 0.72 for G8, 0.72 for the modified G

153 y as a bridge to transplant and/or in older, unfit patients who are not candidates for allogeneic HSC

154 A uniform definition of unfit patients will lead to more uniform clinical trials

155 Fortunately, the outcomes of older or unfit patients with acute myeloid leukaemia have substan

156 r own approach to the management of older or unfit patients with acute myeloid leukaemia, including h

157 fully oral regimen and safe in most older or unfit patients with acute myeloid leukaemia.

158 oclax and 5-azacitidine (5-AZA) for older or unfit patients with acute myeloid leukemia (AML) improve

159 esents an important new therapy for older or unfit patients with acute myeloid leukemia (AML).

160 R (fludarabine, cyclophosphamide, rituximab)-unfit patients with CLL (n = 67).

161 ration Ven-O improves overall PROs in older, unfit patients with CLL with and without geriatric impai

162 efficacy and toxicity of Ven-Obi in fit and unfit patients with CLL.

163 In unfit patients with high-risk CT findings, perioperative

164 emotherapeutic regimens for the treatment of unfit patients with metastatic urothelial carcinoma.

165 rvival in older (aged 75 years or older) and unfit patients with newly diagnosed acute myeloid leukae

166 netoclax and 5-AZA in older (>= 60 years) or unfit patients with newly diagnosed AML.

167 5-AZA is an effective regimen among older or unfit patients with newly diagnosed AML.

168 nd resistance training is safe in physically unfit patients with quiescent Inflammatory Bowel Disease

169 anageable safety and encouraging efficacy in unfit patients with R/R AML.

170 In unfit patients without these high-risk CT findings, the

171 According to this definition, unfit patients would meet at least one of the following

172 to patients resistant to chemotherapy and to unfit patients, unable to tolerate intensive chemotherap

173 s with intensive chemotherapy in F-fit and F-unfit patients.

174 ients or between EVAR and no intervention in unfit patients.

175 and visceral adiposity (-0.2; P = 0.01) than unfit peers.

176 The disproportionate loss of psychologically unfit personnel early in training creates a "healthy war

177 ations in which, through somatic mutations, "unfit" stem cells gain a measure of fitness by altering

178 inantly associated with a selective sweep of unfit subclones.

179 that such severely mutated viruses were too unfit to be detected or that the resistance gain offered

180 d shorter than in canonical ITAMs, making it unfit to bind the tandem SH2 of Syk.

181 ical mechanistic studies, as each of them is unfit to clarify the operative mechanisms alone.

182 ns' warnings to patients who are potentially unfit to drive are a medical intervention intended to pr

183 ns' warnings to patients who are potentially unfit to drive may contribute to a decrease in subsequen

184 physician who judged them to be potentially unfit to drive.

185 uses complex categorical stimuli, making it unfit to quantify the effect of feature similarity on in

186 at least 6 months for patients unwilling or unfit to receive chemotherapy, were randomly assigned (2

187 ermediate-stage tumours or who are medically unfit to receive chemotherapy.

188 ly affecting older adults, many patients are unfit to receive intensive chemotherapy, and although he

189 derlying neurochemical disturbances that are unfit to the granularity of our analyses.

190 a treatment option for patients unwilling or unfit to undergo surgery.

191 We show here that IgE(+) GC B cells are unfit to undergo the conventional GC differentiation pro

192 dren are becoming overweight, unhealthy, and unfit, understanding the neurocognitive benefits of an a

193 When grouped into categories of fit and unfit (upper 80% and lower 20% of CRF distribution, resp

194 ns is not feasible in patients who are older/unfit, which represents a considerable proportion of pat

195 ould be considered in patients who are older/unfit who did not have bone marrow involvement at initia

196 tober 2020 for use in older patients who are unfit with acute myeloid leukemia (AML) combined with ei

197 CI=0.19 to 2.4) among fit (>6.5 METs) versus unfit women.

198 alleles and a decrease in the expression of (unfit) Y-linked alleles.